Dymista^® - twice as effective as monotherapy

Dymista^® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

The combination spray containing azelastine (AZ) and fluticasone (FP), Dymista^®, has been shown to be twice as effective as fluticasone propionate or azelastine alone at treating the entire rhinitis symptom spectrum:^1,2

In a randomized, double-blind, placebo-controlled, 2-week trial involving 779 patients with moderate-to-severe seasonal allergic rhinitis, Dymista^® (MP29-02) administered as one spray to each nostril twice-daily provided greater nasal and ocular symptom improvement than azelastine (AZ) or fluticasone propionate (FP) administered alone (one spray to each nostril twice-daily).¹